|11/29/16||Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted|
|REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced acceptance of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate. This represents the first EMA submission and acceptance for Coherus BioSciences.
The CHS-1701 MAA is supported by biosimilarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing ... |
|11/17/16||Coherus BioSciences Announces New Employment Inducement Grants|
|REDWOOD CITY, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective November 17, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 80,500 shares of the company’s common stock with a per share exercise price of $28.00, the closing trading price on the grant date. In addition, 45,000 shares of stock were granted to a Vice President, Regulatory Affairs new hi... |
|11/09/16||Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results|
|Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond
REDWOOD CITY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2016.
Corporate Highlights for the Third Quarter 2016 Include:
Oncology therapeutic franchise:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)
U.S. Food and Drug... |
|11/07/16||Coherus BioSciences Receives Decision Denying Institution of the ‘166 IPR Related to AbbVie’s HUMIRA® Formulation|
|Management to host a call to discuss the decision
REDWOOD CITY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus’ petition for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,114,166 (the “’166 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.
“While we are disappointe... |